Megakaryocytes are the largest cells in the bone marrow, and their main role is to produce platelets, the cell fragments that plug damaged blood vessels and start clotting. In health, they sit next to marrow blood vessels and release thousands of platelets each, keeping the platelet count steady. In disease, too many, too few, or abnormally shaped megakaryocytes lead to high or low platelet counts, bleeding, clotting, or marrow scarring, as seen in essential thrombocythemia, primary myelofibrosis, and immune thrombocytopenia.
Looking at megakaryocytes on a marrow sample is one of the most informative things a hematologist does. Their number and appearance often tell us whether a platelet problem starts in the marrow or elsewhere in the body.
What Are Megakaryocytes?
Understanding megakaryocytes in bone marrow begins with their size. A mature megakaryocyte is many times larger than a red blood cell, with a single large, multi-lobed nucleus. Despite their prominence under the microscope, they make up only a small fraction of all marrow cells, well under one percent.
Like all blood cells, they originate from hematopoietic stem cells. As they mature, they go through endomitosis: they copy their DNA repeatedly without dividing. The result is a polyploid cell carrying many sets of chromosomes, commonly 16 or more copies instead of the usual two. This extra DNA supports a huge cell body packed with the proteins and granules that each platelet will need.
How Megakaryocytes Make Platelets
Platelet production follows a well-defined sequence that is part of normal blood cell development:
- Commitment: a stem cell’s descendants commit to the megakaryocyte line.
- Endomitosis: the young megakaryocyte enlarges and multiplies its DNA.
- Cytoplasmic maturation: the cell fills with granules and an internal membrane system that becomes the platelet surface.
- Proplatelet formation: the megakaryocyte pushes long, beaded extensions through the walls of marrow blood vessels (sinusoids).
- Release: blood flow shears the extensions into individual platelets.
A single megakaryocyte produces thousands of platelets. Those platelets circulate for about 7 to 10 days before being cleared, mainly by the spleen and liver, so the marrow must replace them continuously.
Thrombopoietin: the master regulator
The hormone thrombopoietin (TPO), made mainly by the liver, controls how many megakaryocytes form and how fast they mature. Circulating platelets bind and remove TPO, so when platelets are low, more TPO is free to stimulate the marrow, and when platelets are high, TPO levels fall. This feedback loop explains why TPO-mimicking drugs are used to treat low platelet counts.
Roles Beyond Platelet Production
Megakaryocytes do more than make platelets. They sit close to stem cells in specialized marrow “niches” and release signaling molecules that help keep those stem cells quiet and stable. They also produce growth factors that influence the surrounding supportive (stromal) cells and the fibrous framework of the marrow.
This second role matters in disease. When abnormal megakaryocytes release too many of these growth factors, they can stimulate fibroblasts to lay down scar tissue, which is a central feature of myelofibrosis.
Megakaryocytes in Disease
Megakaryocyte problems fall under the broader group of hematological disorders. The table below summarizes the main patterns a hematologist looks for.
| Condition | Megakaryocytes in the marrow | Effect on platelets |
|---|---|---|
| Immune thrombocytopenia (ITP) | Normal or increased | Low count; platelets destroyed in circulation |
| Aplastic anemia | Markedly reduced or absent | Low count from production failure |
| Reactive thrombocytosis | Increased, normal appearance | High count in response to infection, inflammation, or iron deficiency |
| Essential thrombocythemia | Increased, large, with hyperlobulated nuclei | Persistently high count |
| Primary myelofibrosis | Increased, clustered, abnormally shaped | Variable; marrow scarring |
| Myelodysplastic syndromes | Often small, with poorly lobed nuclei | Often low; ineffective production |
Myeloproliferative neoplasms
In essential thrombocythemia and primary myelofibrosis, acquired mutations in the JAK2, CALR, or MPL genes switch on the signaling pathway normally controlled by thrombopoietin. The result is megakaryocytes that grow and multiply without the usual brakes. Patients may have thrombocytosis with a risk of both clots and, at very high counts, bleeding.
Low platelet states
When platelets are low, marrow megakaryocytes help distinguish the cause. Plentiful megakaryocytes suggest platelets are being made but destroyed or used up, as in ITP. Scarce megakaryocytes point to a production failure, such as aplastic anemia or marrow infiltration by leukemia.
Symptoms, Diagnosis, and Testing
Megakaryocytes do not cause symptoms directly. Problems show up through the platelet count. Low counts cause easy bruising, pinpoint skin spots (petechiae), nosebleeds, and heavy periods, while high counts can be linked to headaches, burning in the hands or feet, or clots in veins and arteries, part of the spectrum of clotting disorders.
Evaluation usually proceeds in steps:
- Complete blood count and blood film to check platelet number and size
- Molecular tests on blood for JAK2, CALR, and MPL mutations when a myeloproliferative neoplasm is suspected
- Bone marrow aspirate and trephine biopsy to assess megakaryocyte number, shape, clustering, and any fibrosis
- Cytogenetics and flow cytometry where a marrow cancer is possible
The trephine biopsy is particularly valuable because megakaryocyte clustering and marrow fibrosis are best seen in an intact core of tissue rather than a liquid aspirate.
Treatment and Management
Treatment targets the underlying disorder rather than the megakaryocytes alone. In hematology practice, common approaches include:
- Hydroxyurea or other cytoreductive drugs to lower platelet counts in high-risk essential thrombocythemia
- JAK inhibitors such as ruxolitinib to reduce spleen size and symptoms in myelofibrosis
- Low-dose aspirin for selected patients with myeloproliferative neoplasms to lower clot risk
- Thrombopoietin receptor agonists to stimulate megakaryocytes in immune thrombocytopenia
- Platelet transfusions for bleeding or before procedures when counts are severely low
Research into megakaryocyte biology continues, including efforts to grow platelets from stem cells in the laboratory, which could one day reduce reliance on donated platelets.
Key Takeaways
- Megakaryocytes are large, polyploid marrow cells that produce all circulating platelets.
- Thrombopoietin, made in the liver, regulates their growth through a feedback loop with the platelet count.
- They also support stem cell niches and, when abnormal, drive marrow fibrosis.
- Megakaryocyte number and shape on a marrow biopsy help diagnose ITP, aplastic anemia, and myeloproliferative neoplasms.
- See a doctor for unexplained bruising, bleeding, clots, or a platelet count persistently outside the normal range.
Frequently Asked Questions
How many platelets does one megakaryocyte make?
Each megakaryocyte releases thousands of platelets over its lifespan. Because platelets survive only about a week to ten days, the marrow must keep producing them constantly.
What does “increased megakaryocytes” on a bone marrow report mean?
It means the marrow is making more platelet-producing cells than usual. This can be a normal response to platelet destruction, as in ITP, or a sign of a myeloproliferative neoplasm, so the shape of the cells and other results determine which applies.
Can you have low platelets with normal megakaryocytes?
Yes. In immune thrombocytopenia, the marrow often has normal or increased megakaryocytes, but antibodies destroy platelets after they are released. An enlarged spleen can also trap platelets despite normal production.
Are megakaryocytes found outside the bone marrow?
Small numbers circulate and can be found in other organs, including the lungs. The bone marrow, however, is the main site of platelet production in adults.
